Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
05 2020
Historique:
received: 21 10 2019
revised: 23 01 2020
accepted: 17 02 2020
pubmed: 28 3 2020
medline: 16 11 2021
entrez: 28 3 2020
Statut: ppublish

Résumé

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or

Identifiants

pubmed: 32213540
pii: 2159-8290.CD-19-1014
doi: 10.1158/2159-8290.CD-19-1014
pmc: PMC8292921
mid: NIHMS1723894
doi:

Substances chimiques

Immunoconjugates 0
trastuzumab deruxtecan 5384HK7574
Receptor, ErbB-2 EC 2.7.10.1
Trastuzumab P188ANX8CK
Camptothecin XT3Z54Z28A

Types de publication

Clinical Trial, Phase I Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

688-701

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

©2020 American Association for Cancer Research.

Références

J Chemother. 2019 Apr;31(2):95-104
pubmed: 30739598
Cancer Sci. 2016 Jul;107(7):1039-46
pubmed: 27166974
Nat Med. 2018 May;24(5):638-646
pubmed: 29686424
Ann Oncol. 2019 Mar 1;30(3):447-455
pubmed: 30596880
Eur J Cancer. 2019 Mar;109:28-35
pubmed: 30685684
J Thorac Oncol. 2017 May;12(5):833-842
pubmed: 28167203
Lung Cancer. 2012 Apr;76(1):123-7
pubmed: 22325357
J Natl Compr Canc Netw. 2017 Apr;15(4):504-535
pubmed: 28404761
Ann Oncol. 2018 May 1;29(5):1108-1119
pubmed: 29659677
Cancer Med. 2019 Apr;8(4):1434-1441
pubmed: 30762300
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Cancer. 2017 Nov 1;123(21):4099-4105
pubmed: 28743157
Cancer Treat Rev. 2018 Jan;62:61-73
pubmed: 29175677
Bioorg Med Chem Lett. 2016 Mar 15;26(6):1542-1545
pubmed: 26898815
J Clin Oncol. 2013 Jun 1;31(16):1997-2003
pubmed: 23610105
Cancer Cell. 2018 Nov 12;34(5):792-806.e5
pubmed: 30449325
J Clin Med. 2018 Oct 15;7(10):
pubmed: 30326612
Lancet Oncol. 2017 Nov;18(11):1512-1522
pubmed: 29037983
Clin Cancer Res. 1995 Oct;1(10):1189-94
pubmed: 9815911
Anticancer Res. 2011 Dec;31(12):4631-6
pubmed: 22199341
Lancet Oncol. 2016 Jun;17(6):738-746
pubmed: 27108243
Cancer Cell. 2019 Oct 14;36(4):444-457.e7
pubmed: 31588020
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81
pubmed: 22908275
Lancet Oncol. 2014 Jun;15(7):689-99
pubmed: 24793816
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
Cancer Res. 2005 Mar 1;65(5):1642-6
pubmed: 15753357
Clin Cancer Res. 2003 Nov 1;9(14):5238-43
pubmed: 14614004
Ann Oncol. 2004 Jan;15(1):19-27
pubmed: 14679114
Mod Pathol. 2012 Dec;25(12):1566-73
pubmed: 22899293
Cancer Discov. 2013 Nov;3(11):1238-44
pubmed: 23950206
Cancer Res. 2008 Nov 15;68(22):9280-90
pubmed: 19010901
Clin Cancer Res. 2019 Jan 1;25(1):64-72
pubmed: 30206164
J Clin Oncol. 2018 Jul 10;36(20):2044-2051
pubmed: 29584549
Cancer Cell. 2006 Jul;10(1):25-38
pubmed: 16843263
Ann Oncol. 2015 Jul;26(7):1421-7
pubmed: 25899785
Hum Pathol. 2010 Nov;41(11):1577-85
pubmed: 20656317
Lancet Oncol. 2019 Apr;20(4):518-530
pubmed: 30857956
Nature. 2004 Sep 30;431(7008):525-6
pubmed: 15457249
J Clin Oncol. 2006 May 20;24(15):2376-85
pubmed: 16710036
Future Oncol. 2018 Jul;14(16):1629-1645
pubmed: 29701076
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
J Clin Oncol. 2007 Jun 1;25(16):2218-24
pubmed: 17538166
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
J Thorac Oncol. 2018 Feb;13(2):273-279
pubmed: 29313813
Front Oncol. 2018 Apr 03;8:89
pubmed: 29670855
Lancet Oncol. 2019 Jun;20(6):816-826
pubmed: 31047803
Lancet Oncol. 2019 Jun;20(6):827-836
pubmed: 31047804
J Thorac Oncol. 2010 Dec;5(12):1922-32
pubmed: 21155183

Auteurs

Junji Tsurutani (J)

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan. tsurutaj@med.showa-u.ac.jp lib1@mskcc.org.
Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.

Hiroji Iwata (H)

Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Ian Krop (I)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Pasi A Jänne (PA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Toshihiko Doi (T)

Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.

Shunji Takahashi (S)

Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Haeseong Park (H)

Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.

Charles Redfern (C)

Medical Oncology, Sharp HealthCare, San Diego, California.

Kenji Tamura (K)

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Trisha M Wise-Draper (TM)

Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio.

Kaku Saito (K)

Research and Development, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

Masahiro Sugihara (M)

Biostatistics and Data Management, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

Jasmeet Singh (J)

Clinical Safety, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.

Takahiro Jikoh (T)

Oncology Research and Development, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.

Gilles Gallant (G)

Oncology Research and Development, Daiichi Sankyo, Inc., Basking Ridge, New Jersey.

Bob T Li (BT)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. tsurutaj@med.showa-u.ac.jp lib1@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH